Table 1 Tumor types and chemotherapy regimens used by cohort for participants in this study
From: Safety and feasibility of fasting in combination with platinum-based chemotherapy
Cancer type | Chemotherapy regimen | Disease state |
|---|---|---|
24 h cohort | ||
Urothelial | Gemcitabine + Cisplatin | Metastatic |
Urothelial | Gemcitabine + Cisplatin | Adjuvant |
NSCLC | Gemcitabine + Cisplatin | Metastatic |
Urothelial | Gemcitabine + Cisplatin | Neoadjuvant |
Ovarian | Carboplatin + Paclitaxel | Adjuvant |
Uterine | Carboplatin + nab-Paclitaxel | Metastatic |
48 h cohort | ||
Ovarian | Carboplatin + Paclitaxel | Adjuvant |
Breast | TCH | Adjuvant |
Breast | TCH | Adjuvant |
Breast | TCH | Adjuvant |
Urothelial | Gemcitabine + Cisplatin | Neoadjuvant |
Breast | TCH | Adjuvant |
Ovarian | Carboplatin + Paclitaxel | Metastatic |
72 h cohort | ||
Ovarian | Carboplatin + Paclitaxel | Metastatic |
Urotheliala | Gemcitabine + Cisplatin | Neoadjuvant |
Uterine | Carboplatin + Paclitaxel | Adjuvant |
Breast | TCH | Neoadjuvant |
Urothelial | Gemcitabine + Cisplatin | Neoadjuvant |
Ovarian | Carboplatin + Paclitaxel | Adjuvant |
Ovarian | Carboplatin + Paclitaxel | Metastatic |